Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07490509 | Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer(DOSABEMA) | not yet recruiting | Phase 4 | 235 | Poitiers University HospitalOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07630948 | Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer(riboADHERE) | not yet recruiting | Phase 4 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07583134 | Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery(B-BIT) | not yet recruiting | Phase 4 | 100 | Chang-Ik YoonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07436663 | Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC(SGLT2i/DPPi) | not yet recruiting | Phase 4 | 150 | Tanta UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | not yet recruiting | Phase 4 | 78 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07254221 | Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients(ROSUBREAST) | not yet recruiting | Phase 4 | 400 | Shiraz University of Medical SciencesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05871437 | Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules | not yet recruiting | Phase 4 | 232 | Fudan UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07093931 | Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer | not yet recruiting | Phase 4 | 468 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06777537 | Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer | not yet recruiting | Phase 4 | 200 | Shandong UniversityOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | not yet recruiting | Phase 4 | 30 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04929548 | Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP | not yet recruiting | Phase 4 | 20 | Wuhan UniversityOTHER | 0 | Jan 5, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials